Table 2.

Participants’ medication regime.

PH medicine(s)	Frequency	Percent
Ambrisentan monotherapy	23	8.2
Bosentan monotherapy	33	11.7
Sildenafil monotherapy	104	36.9
Tadalafil monotherapy	2	0.7
Iloprost monotherapy	1	0.4
Epoprostenol monotherapy	1	0.4
ERA + PDE5i	86	30.5
Iloprost (nebulized) + PDE5i	7	2.5
IV/SC Prostanoid + ERA	1	0.4
IV/SC Prostanoid + PDE5i	13	4.6
Trial drug + ERA + /− PDE5i	11	4.0%
Total	282